Notice to Jaipur hospital for conducting trials of Patanjali drug


PTI, Jun 26, 2020, 9:08 PM IST

Jaipur: Rajasthan’s Health Department has served a notice to Jaipur’s NIMS hospital seeking an explanation on conducting trials of Patanjali Ayurved’s drug Coronil on coronavirus patients, an official said on Friday.

“We served notice to the hospital on Wednesday evening seeking explanation in three days. The hospital did not inform the state government nor sought permission,” Chief Medical and Health Officer, Jaipur, Dr Narottam Sharma said.

He said the reply from National Institute of Medical Science (NIMS), Jaipur is awaited.

The launch of the drug by yoga guru Ramdev on Tuesday triggered a controversy after which the Ayush Ministry sought all information on its trial and put a ban on advertising it as a drug to cure coronavirus.

The Rajasthan government has clarified that the drug cannot be not used as a medicine in the state without the permission of the Ministry of AYUSH.

State Health Minister Raghu Sharma had said on Wednesday that strict action would be taken against the seller as per the rules in case of sale of any drug as a medicine to treat the coronavirus infection.

At the Coronil launch, the company had claimed that its medicine can cure the contagious disease within seven days.

It said Coronil, taken along with another product developed by it, had shown a 100 per cent success rate in clinical trials on infected patients, except those on life support.

Ramdev said the medicines were developed by Patanjali Research Center, Haridwar in association with privately-owned National Institute of Medical Science (NIMS), Jaipur.

The Uttarakhand government will serve a notice to Patanjali Ayurved for launching a drug claiming to be a cure for COVID-19 when it had only applied for a licence to manufacture an immunity booster against cough and fever.

Apart from the notice from the Uttarakhand government, the Haridwar-based firm could also face litigation in Bihar. A complaint has been filed against it in a Muzaffarpur court over its claim.

A complainant approached the court seeking the registration of an FIR against Ramdev and company chairman Acharya Balkrishna, alleging that they put at risk the lives of lakhs of people by claiming to have developed a COVID-19 cure.

Chief Judicial Magistrate Mukesh Kumar posted the matter for hearing on June 30.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

EVMs destroyed as two groups of villagers clash in Chamarajanagar district

Banjarumale hamlet in Belthangady records 100 per cent voting

Board exams twice a year from 2025: MoE asks CBSE to work out logistics, no plan for semesters

Lok Sabha 2024: Tribal hamlet of Banjarumale in Belthangady records 100% voter turnout

Padubidri: Speeding car collides with electric pole, one dead

Bengaluru eateries butter up voter turnout with free dosa

Low voter turnout in Karnataka: Only 38.23% cast votes in 14 LS segments during first half of the day

Related Articles More

Congress to discuss candidates for Amethi, Raebareli seats on Saturday

Cache of arms including foreign-made revolvers seized by CBI in Sandeshkhali raids

24 Indian Fishermen Released from Sri Lankan Detention, Repatriated to India

SC verdict on EVM tight slap to Congress-led opposition: PM Modi in Bihar rallies

Board exams twice a year from 2025: MoE asks CBSE to work out logistics, no plan for semesters

MUST WATCH

Skin Rash, Causes, Signs and Symptoms

11 bullets found in python’s body!

K. Jayaprakash Hegde Sharing His Memories

Grafting Jack Anil

Heat Illness


Latest Additions

Patanjali Foods to evaluate proposal to buy Patanjali Ayurved’s non-food business

Congress to discuss candidates for Amethi, Raebareli seats on Saturday

BJP’s CT Ravi Booked for Promoting Hatred and Enmity Through Social Media Post

Elections held in 14 LS segments in Karnataka, voter turnout nearly 64 per cent till 5 pm

‘PM is scared, may even shed tears on stage’: Rahul Gandhi’s fresh salvo at Modi

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.